Repository logo
 
Publication

CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours

datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorSilva, Ana Luísa
dc.contributor.authorBarry, Sayka
dc.contributor.authorLopes-Pinto, Mariana
dc.contributor.authorJoaquim, Rita
dc.contributor.authorMiranda, Catarina
dc.contributor.authorReis, Fábio
dc.contributor.authorMiranda, Micaella
dc.contributor.authorMatos, Paulo
dc.contributor.authorSuleyman, Oniz
dc.contributor.authorOliveira, Tiago
dc.contributor.authorLópez-Presa, Dolores
dc.contributor.authorBorrecho, Gonçalo
dc.contributor.authorTortosa, Francisco
dc.contributor.authorFaria, Claúdia C.
dc.contributor.authorKorbonits, Márta
dc.contributor.authorMarques, Pedro
dc.date.accessioned2025-11-12T15:58:48Z
dc.date.available2025-11-12T15:58:48Z
dc.date.issued2025-03-24
dc.descriptionThis paper is part of a special collection highlighting the work of emerging leaders in the endocrine cancer field.
dc.description.abstractThe crosstalk between tumour cells and microenvironment components in pituitary neuroendocrine tumours (PitNETs), including chemokines, may impact tumour behaviour and clinical outcomes. CCL2 was previously identified as a key chemokine in PitNETs, but its role remains unknown. We aimed to study the role of CCL2 in defining the phenotype and clinical outcomes of PitNETs and in regulating macrophage chemotaxis, epithelial-to-mesenchymal transition (EMT) and angiogenesis. We studied CCL2 and E-cadherin expression, macrophages (CD68 and CD163) and vessels (CD31) in samples from 86 PitNET patients. Higher CCL2 mRNA expression was found in patients who required multimodal and multiple treatments and had active disease at the last follow-up. Higher CCL2 immunoreactivity was observed in patients with larger PitNETs. Among somatotroph tumours, CCL2 mRNA expression correlated with serum IGF-1 at the last follow-up. CCL2 mRNA expression levels correlated negatively with CDH1 expression and with E-cadherin complete membranous staining. In vitro, CCL2 downregulated E-cadherin expression in GH3 cells but did not affect cell morphology or migration. CCL2 expression correlated with the number of vessels, vessel perimeter and vessel area in PitNETs but not with PitNET-infiltrating macrophages. Our data suggest that CCL2 may lead to (or is at least a predictive marker of) poorer clinical outcomes and more difficult-to-treat PitNETs, potentially through its regulatory effects on different tumour-related mechanisms beyond immune cell chemotaxis, including in the activation of the EMT pathway and modulation of angiogenesis in PitNETs. Further studies are needed to corroborate our findings and to validate CCL2 as a potential predictive marker and therapeutic target in PitNETs.eng
dc.description.sponsorshipPM was supported by a Pilot Project Award from the Neuroendocrine Tumor research Foundation (NETRF) and by the Maria de Sousa Prize awarded by Fundação BIAL (BIAL Foundation) and Ordem dos Medicos (Portuguese Medical Order).
dc.identifier.citationEndocr Relat Cancer. 2025 May 1;32(5):e240293. doi: 10.1530/ERC-24-0293. Epub 2025 Mar 24
dc.identifier.doi10.1530/ERC-24-0293
dc.identifier.issn1351-0088
dc.identifier.pmid40063010
dc.identifier.urihttp://hdl.handle.net/10400.18/10597
dc.language.isoeng
dc.peerreviewedyes
dc.publisherBioScientifica
dc.relation.hasversionhttps://erc.bioscientifica.com/view/journals/erc/32/5/ERC-24-0293.xml
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCCL2
dc.subjectAngiogenesis
dc.subjectEpithelial-to-Mesenchymal Transition
dc.subjectMicroenvironment
dc.subjectPituitary Neuroendocrine Tumou
dc.subjectVias de Transdução de Sinal
dc.titleCCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumourseng
dc.typejournal article
dcterms.referenceshttps://erc.bioscientifica.com/supplemental/journals/erc/32/5/ERC-24-0293.xml/supplementary_materials.pdf?t:state:client=GdEIZOFln9AQYjwi3/7bYqhq+Dw=: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
dspace.entity.typePublication
oaire.citation.issue5
oaire.citation.startPagee240293
oaire.citation.titleEndocrine-Related Cancer
oaire.citation.volume32
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
SilvaA 2025 ERC.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description: